345 related articles for article (PubMed ID: 31014053)
1. [Application of radiomics captured from CT to predict the EGFR mutation status and TKIs therapeutic sensitivity of advanced lung adenocarcinoma].
Yang CS; Chen WD; Gong GZ; Li ZJ; Qiu QT; Yin Y
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):282-287. PubMed ID: 31014053
[No Abstract] [Full Text] [Related]
2. Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma.
Yang C; Chen W; Gong G; Li Z; Qiu Q; Yin Y
Transl Cancer Res; 2020 Nov; 9(11):6683-6690. PubMed ID: 35117278
[TBL] [Abstract][Full Text] [Related]
3. A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma.
Lu X; Li M; Zhang H; Hua S; Meng F; Yang H; Li X; Cao D
Phys Med Biol; 2020 Mar; 65(5):055012. PubMed ID: 31978901
[TBL] [Abstract][Full Text] [Related]
4. Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
Yang X; Dong X; Wang J; Li W; Gu Z; Gao D; Zhong N; Guan Y
Oncologist; 2019 Nov; 24(11):e1156-e1164. PubMed ID: 30936378
[TBL] [Abstract][Full Text] [Related]
5. CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses.
Mei D; Luo Y; Wang Y; Gong J
Cancer Imaging; 2018 Dec; 18(1):52. PubMed ID: 30547844
[TBL] [Abstract][Full Text] [Related]
6. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
7. [Efficacy of first generation EGFR-TKIs and chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations].
Li HX; Wang ZZ; Zhang GW; Zhang MN; Zheng XX; Yang JP; Ma ZY; Wang HJ
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):783-791. PubMed ID: 31648503
[No Abstract] [Full Text] [Related]
8. Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation.
Cheng B; Deng H; Zhao Y; Xiong J; Liang P; Li C; Liang H; Shi J; Li J; Xiong S; Lai T; Chen Z; Wu J; Qian T; Huan W; Ng MTA; He J; Liang W
Eur Radiol; 2022 Sep; 32(9):5869-5879. PubMed ID: 35348863
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.
Kim H; Park CM; Keam B; Park SJ; Kim M; Kim TM; Kim DW; Heo DS; Goo JM
PLoS One; 2017; 12(11):e0187500. PubMed ID: 29099855
[TBL] [Abstract][Full Text] [Related]
10. CT radiomics-based prediction of anaplastic lymphoma kinase and epidermal growth factor receptor mutations in lung adenocarcinoma.
Choe J; Lee SM; Kim W; Do KH; Kim S; Choi S; Seo JB
Eur J Radiol; 2021 Jun; 139():109710. PubMed ID: 33862316
[TBL] [Abstract][Full Text] [Related]
11. Detailed identification of epidermal growth factor receptor mutations in lung adenocarcinoma: Combining radiomics with machine learning.
Li S; Luo T; Ding C; Huang Q; Guan Z; Zhang H
Med Phys; 2020 Aug; 47(8):3458-3466. PubMed ID: 32416013
[TBL] [Abstract][Full Text] [Related]
12. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling.
Jia TY; Xiong JF; Li XY; Yu W; Xu ZY; Cai XW; Ma JC; Ren YC; Larsson R; Zhang J; Zhao J; Fu XL
Eur Radiol; 2019 Sep; 29(9):4742-4750. PubMed ID: 30778717
[TBL] [Abstract][Full Text] [Related]
13. CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma.
Shen TX; Liu L; Li WH; Fu P; Xu K; Jiang YQ; Pan F; Guo Y; Zhang MC
Cancer Imaging; 2019 Jun; 19(1):34. PubMed ID: 31174617
[TBL] [Abstract][Full Text] [Related]
14. Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
Yang X; Fang C; Li C; Gong M; Yi X; Lin H; Li K; Yu X
Front Oncol; 2022; 12():904983. PubMed ID: 35875167
[TBL] [Abstract][Full Text] [Related]
15. Accurate prediction of epidermal growth factor receptor mutation status in early-stage lung adenocarcinoma, using radiomics and clinical features.
Zhu H; Song Y; Huang Z; Zhang L; Chen Y; Tao G; She Y; Sun X; Yu H
Asia Pac J Clin Oncol; 2022 Dec; 18(6):586-594. PubMed ID: 35098682
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature.
Zhang X; Lu B; Yang X; Lan D; Lin S; Zhou Z; Li K; Deng D; Peng P; Zeng Z; Long L
Eur Radiol; 2023 Feb; 33(2):825-835. PubMed ID: 36166088
[TBL] [Abstract][Full Text] [Related]
17. Role of intratumoral and peritumoral CT radiomics for the prediction of EGFR gene mutation in primary lung cancer.
Yamazaki M; Yagi T; Tominaga M; Minato K; Ishikawa H
Br J Radiol; 2022 Dec; 95(1140):20220374. PubMed ID: 36115683
[TBL] [Abstract][Full Text] [Related]
18. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma.
Chang C; Zhou S; Yu H; Zhao W; Ge Y; Duan S; Wang R; Qian X; Lei B; Wang L; Liu L; Ruan M; Yan H; Sun X; Xie W
Eur Radiol; 2021 Aug; 31(8):6259-6268. PubMed ID: 33544167
[TBL] [Abstract][Full Text] [Related]
19. Early acquired resistance to EGFR-TKIs in lung adenocarcinomas before radiographic advanced identified by CT radiomic delta model based on two central studies.
Li X; Zhang C; Li T; Lin X; Wu D; Yang G; Cao D
Sci Rep; 2023 Sep; 13(1):15586. PubMed ID: 37730961
[TBL] [Abstract][Full Text] [Related]
20. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
